Towards targeted therapy for Angelman syndrome

Bibliography

• Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med. 2010;12(7):385–395.
   PubMed Web of Science ®Google Scholar
• Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87–95.
   PubMed Web of Science ®Google Scholar
• Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70–73.
   PubMed Web of Science ®Google Scholar
• Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15(1):74–77.
   PubMed Web of Science ®Google Scholar
• Buiting K, Clayton-Smith J, Driscoll DJ, et al. Clinical utility gene card for: Angelman syndrome. Eur J Hum Genet. 2015;23(2). DOI:10.1038/ejhg.2014.93.
   Web of Science ®Google Scholar
• Jiang Y-H, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998;21(4):799–811.
   PubMed Web of Science ®Google Scholar
• Gustin RM, Bichell TJ, Bubser M, et al. Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis. 2010;39(3):283–291.
   PubMed Web of Science ®Google Scholar
• Daily J, Smith AG, Weeber EJ. Spatial and temporal silencing of the human maternal UBE3A gene. Eur J Paediatr Neurol. 2012;16(6):587–591.
   PubMed Web of Science ®Google Scholar
• Abeliovich A, Paylor R, Chen C, et al. PKCγ mutant mice exhibit mild deficits in spatial and contextual learning. Cell. 1993;75(7):1263–1271.
   PubMed Web of Science ®Google Scholar
• Bach ME, Hawkins RD, Osman M, et al. Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. Cell. 1995;81(6):905–915.
   PubMed Web of Science ®Google Scholar
• Crawley JN, Belknap JK, Collins A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology. 1997;132(2):107–124.
   PubMed Web of Science ®Google Scholar
• Weeber EJ, Jiang Y-H, Elgersma Y, et al. Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neuroscience. 2003;23(7):2634–2644.
   PubMed Web of Science ®Google Scholar
• Van Woerden GM, Harris KD, Hojjati MR, et al. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation. Nat Neurosci. 2007;10(3):280–282.
   PubMed Web of Science ®Google Scholar
• Kaphzan H, Buffington SA, Jung JI, et al. Alterations in intrinsic membrane properties and the axon initial segment in a mouse model of Angelman syndrome. J Neurosci. 2011;31(48):17637–17648.
   PubMed Web of Science ®Google Scholar
• Kaphzan H, Buffington SA, Ramaraj AB, et al. Genetic reduction of the α1 subunit of Na/K-ATPase corrects multiple hippocampal phenotypes in Angelman syndrome. Cell Rep. 2013;4(3):405–412.
   PubMed Web of Science ®Google Scholar
• Shonesy BC, Jalan-Sakrikar N, Cavener VS, et al. CaMKII: a molecular substrate for synaptic plasticity and memory. Prog Mol Biol Transl Sci. 2014;122:61–87.
   PubMed Web of Science ®Google Scholar
• Muller D, De Roo M, Nikonenko I. Activity-mediated structural plasticity of dendritic spines. In: Pickel VM, Segal M, editors. Synapse: structure and function. New York, NY: Elsevier Science; 2013. p. 377.
   Google Scholar
• Dindot SV, Antalffy BA, Bhattacharjee MB, et al. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet. 2008;17(1):111–118.
   PubMed Web of Science ®Google Scholar
• Arai A, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007;8(5):583–602.
   PubMed Web of Science ®Google Scholar
• Lynch G, Rex CS, Chen LY, et al. The substrates of memory: defects, treatments, and enhancement. Eur J Pharmacol. 2008;585(1):2–13.
   PubMed Web of Science ®Google Scholar
• Simmons DA, Rex CS, Palmer L, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci. 2009;106(12):4906–4911.
   PubMed Web of Science ®Google Scholar
• Kramár EA, Chen LY, Lauterborn JC, et al. BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats. Neurobiol Aging. 2012;33(4):708–719.
   PubMed Web of Science ®Google Scholar
• Baudry M, Kramar E, Xu X, et al. Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome. Neurobiol Dis. 2012;47(2):210–215.
   PubMed Web of Science ®Google Scholar
• Grieco JC, Ciarlone SL, Gieron-Korthals M, et al. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurol. 2014;14(1):232.
   PubMed Web of Science ®Google Scholar
• Hiesberger T, Trommsdorff M, Howell BW, et al. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999 Oct;24(2):481–489.
   PubMed Web of Science ®Google Scholar
• Strasser V, Fasching D, Hauser C, et al. Receptor clustering is involved in Reelin signaling. Mol Cell Biol. 2004 Feb;24(3):1378–1386.
   PubMed Web of Science ®Google Scholar
• Chen Y, Beffert U, Ertunc M, et al. Reelin modulates NMDA receptor activity in cortical neurons. J Neurosci. 2005 Sep 7;25(36):8209–8216.
   PubMed Web of Science ®Google Scholar
• Beffert U, Weeber EJ, Morfini G, et al. Reelin and cyclin-dependent kinase 5-dependent signals cooperate in regulating neuronal migration and synaptic transmission. J Neurosci. 2004 Feb 25;24(8):1897–1906.
   PubMed Web of Science ®Google Scholar
• Beffert U, Morfini G, Bock HH, et al. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J Biol Chem. 2002 Dec 20;277(51):49958–49964.
   PubMed Web of Science ®Google Scholar
• Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Reviews Neurosci. 2006 Nov;7(11):850–859.
   PubMed Web of Science ®Google Scholar
• Weeber EJ, Beffert U, Jones C, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002 Oct 18;277(42):39944–39952.
   PubMed Web of Science ®Google Scholar
• Qiu S, Weeber EJ. Reelin signaling facilitates maturation of CA1 glutamatergic synapses. J Neurophysiol. 2007 Mar;97(3):2312–2321.
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhao LF, Korwek KM, et al. Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J Neurosci. 2006 Dec 13;26(50):12943–12955.
   PubMed Web of Science ®Google Scholar
• Niu S, Yabut O, D’Arcangelo G. The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J Neurosci. 2008 Oct 8;28(41):10339–10348.
   PubMed Web of Science ®Google Scholar
• Niu S, Renfro A, Quattrocchi CC, et al. Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron. 2004 Jan 8;41(1):71–84.
   PubMed Web of Science ®Google Scholar
• Rogers JT, Rusiana I, Trotter J, et al. Reelin supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine density. Learn Memory. 2011;18(9):558–564.
   PubMed Web of Science ®Google Scholar
• Hethorn WR, Ciarlone SL, Filonova I, et al. Reelin supplementation recovers synaptic plasticity and cognitive deficits in a mouse model for Angelman syndrome. Eur J Neurosci. 2015;41(10):1372–1380.
   PubMed Web of Science ®Google Scholar
• Bailus BJ, Segal DJ. The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders. BMC Neurosci. 2014;15(1):76.
   PubMed Web of Science ®Google Scholar
• Pelc K, Boyd SG, Cheron G, et al. Epilepsy in Angelman syndrome. Seizure. 2008;17(3):211–217.
   PubMed Web of Science ®Google Scholar
• Daily JL, Nash K, Jinwal U, et al. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PLoS One. 2011;6(12):e27221.
   PubMed Web of Science ®Google Scholar
• Silva-Santos S, Van Woerden GM, Bruinsma CF, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest. 2015;125(5):2069–2076.
   PubMed Web of Science ®Google Scholar
• Peters SU, Bird LM, Kimonis V, et al. Double‐blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet. 2010;152A(8):1994–2001.
   PubMed Web of Science ®Google Scholar
• Bird LM, Tan WH, Bacino CA, et al. A therapeutic trial of pro‐methylation dietary supplements in Angelman syndrome. Am J Med Genet. 2011;155(12):2956–2963.
   Web of Science ®Google Scholar
• Jiang Y-H, Lev-Lehman E, Bressler J, et al. Genetics of Angelman syndrome. Am J Hum Genet. 1999;65(1):1–6.
   PubMed Web of Science ®Google Scholar
• Chamberlain SJ, Lalande M. Angelman syndrome, a genomic imprinting disorder of the brain. J Neurosci. 2010;30(30):9958–9963.
   PubMed Web of Science ®Google Scholar
• Huang H-S, Allen JA, Mabb AM, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 2012;481(7380):185–189.
   Web of Science ®Google Scholar
• Meng L, Ward AJ, Chun S, et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518(7539):409–412.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031–1044.
   PubMed Web of Science ®Google Scholar
• Jay V, Becker LE, Chan F, et al. Puppet-like syndrome of Angelman: a pathologic and neurochemical study. Neurology. 1991;41(3):416–422.
   PubMed Web of Science ®Google Scholar
• Chéron G, Servais L, Wagstaff J, et al. Fast cerebellar oscillation associated with ataxia in a mouse model of Angelman syndrome. Neuroscience. 2005;130(3):631–637.
   PubMed Web of Science ®Google Scholar
• Egawa K, Kitagawa K, Inoue K, et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. Sci Transl Med. 2012;4(163):163ra57–63ra57.
   Web of Science ®Google Scholar
• Wallace ML, Burette AC, Weinberg RJ, et al. Maternal loss of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific synaptic defects. Neuron. 2012;74(5):793–800.
   PubMed Web of Science ®Google Scholar
• Valente KD, Koiffmann CP, Fridman C, et al. Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol. 2006;63(1):122.
   PubMedGoogle Scholar
• Thibert RL, Conant KD, Braun EK, et al. Epilepsy in Angelman syndrome: A questionnaire‐based assessment of the natural history and current treatment options. Epilepsia. 2009;50(11):2369–2376.
   PubMed Web of Science ®Google Scholar
• Hermann BP, Seidenberg M, Bell B. The neurodevelopmental impact of childhood onset temporal lobe epilepsy on brain structure and function and the risk of progressive cognitive effects. Prog Brain Res. 2002;135:429–438.
   PubMed Web of Science ®Google Scholar
• Sutula T, Lauersdorf S, Lynch M, et al. Deficits in radial arm maze performance in kindled rats: evidence for long-lasting memory dysfunction induced by repeated brief seizures. J Neuroscience. 1995;15(12):8295–8301.
   PubMed Web of Science ®Google Scholar
• Aldenkamp A, Arends J. The relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive function. Epilepsia. 2004;45(1):54–63.
   PubMed Web of Science ®Google Scholar
• Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848–858.
   PubMed Web of Science ®Google Scholar
• D’Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev. 2001;36(1):60–90.
   PubMedGoogle Scholar
• Laan LA, Renier WO, Arts WFM, et al. Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia. 1997;38(2):195–199.
   PubMed Web of Science ®Google Scholar
• Crawley JN. Behavioral phenotyping strategies for mutant mice. Neuron. 2008;57(6):809–818.
   PubMed Web of Science ®Google Scholar
• Crusio WE. Behavioral genetics of the mouse: volume 1, genetics of behavioral phenotypes. Cambridge: Cambridge University Press; 2013.
   Google Scholar
• Huang H-S, Burns AJ, Nonneman RJ, et al. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res. 2013;243:79–90.
   PubMed Web of Science ®Google Scholar
• McLin JP, Steward O. Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. Eur J Neurosci. 2006;24(8):2191–2202.
   PubMed Web of Science ®Google Scholar
• Schauwecker PE. Seizure-induced neuronal death is associated with induction of c-Jun N-terminal kinase and is dependent on genetic background. Brain Res. 2000;884(1):116–128.
   PubMed Web of Science ®Google Scholar
• Bruinsma CF, Schonewille M, Gao Z, et al. Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model. J Clin Invest. 2015;125(11):4305–4315.
   PubMed Web of Science ®Google Scholar
• Sun J, Liu Y, Moreno S, et al. Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function. J Neurosci. 2015;35(11):4706–4718.
   PubMed Web of Science ®Google Scholar
• Cheron G, Márquez-Ruiz J, Kishino T, et al. Disruption of the LTD dialogue between the cerebellum and the cortex in Angelman syndrome model: a timing hypothesis. Front Syst Neurosci. 2014;8(221):1–9.
   PubMedGoogle Scholar
• Greer PL, Hanayama R, Bloodgood BL, et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell. 2010;140(5):704–716.
   PubMed Web of Science ®Google Scholar